Brief: Algernon Submits Application To Health Canada For Ifenprodil COVID-19 Phase 2B/3 Multinational Clinical Trial
22/04/2020 13:48
April 22 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON SUBMITS APPLICATION TO HEALTH CANADA FOR
IFENPRODIL
COVID-19 PHASE 2B/3 MULTINATIONAL CLINICAL TRIAL
Source text for Eikon: ID:nGNX4VKgXw
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement